Udhayvir Grewal, board-certified medical oncologist at Winship Cancer Institute at Emory Midtown, shared a post on X:
“Happy to share in print The Oncologist– Robust response to Pembrolizumab in a patient with metastatic VIPoma with acquired TMB-high/MSI-high phenotype post treatment with temozolomide.
Bottom line- in a patient with pancreatic or lung NET post exposure to temozolomide: always check liquid biopsy (or tissue if possible) and test for a hypermutated phenotype. In the presence of MSI-H disease or co-occurring DDR alterations, response to ICI can be durable and robust.
Kudos to Charles Shi, Emory University and my colleagues Po Hien Ear, Seth Concors and others for helping put this together.”
Title: Robust response to pembrolizumab in Temozolomide-Associated Hypermutated and Microsatellite Instability-High Functional Pancreatic Neuroendocrine Tumor
Authors: Udhayvir S. Grewal, Charles W. Shi, Saima Muzahir, Po H. Ear, Seth J. Concors, Daniel M. Halperin
Read the article here.
Other articles featuring Udhayvir Grewal on OncoDaily.
